Hickey Edward, Langley Stephen M, Allemby-Smith Oliver, Livesey Steven A, Monro James L
Wessex Cardiothoracic Centre, Southampton, United Kingdom.
Ann Thorac Surg. 2007 Nov;84(5):1564-70. doi: 10.1016/j.athoracsur.2007.02.100.
Differences in sterilization, preservation, and implantation have been implicated in aortic allograft longevity. We report follow-up to 30 years of patients from a single unit who underwent aortic valve replacement with aortic allografts sterilized in antibiotics and refrigerated at 4 degrees C.
Two hundred consecutive patients underwent subcoronary allograft aortic valve replacement and have been followed up to a minimum of 20 and maximum of 30 years. Follow-up was 96% complete. Parametric hazard phase modeling was used to identify incremental predictors of time-related risk.
Early mortality was 1.5%. Kaplan-Meier actuarial survival, including early death, was 81.2% +/- 2.8% (mean +/- standard error of the mean), 58.0% +/- 3.7%, and 52% +/- 5.1% at 10, 20, and 25 years, respectively. Freedom from reoperation for any reason was 86.4% +/- 2.6%, 39.6% +/- 5.2%, and 35.0% +/- 5.4% at 10, 20, and 25 years, respectively. Larger implanted valve, reexploration for bleeding, previous cardiac surgery, and operative rank were independent risks for reoperation. Early mortality in reoperations was 5.1%. Allograft endocarditis has occurred in 6 patients, giving an overall freedom of 94% at 25 years. Seven patients of the original cohort are known to be alive with their original allograft valve in situ, and of these the longest follow-up period is 29.8 years.
The use of antibiotic-sterilized allografts for subcoronary aortic valve replacement confers low operative mortality and excellent long-term survival with durability matching any other nonmechanical device. Significantly reduced time-related risk of reoperation and excellent internal to external diameter ratio renders allograft aortic valve replacement especially ideal for smaller roots.
主动脉同种异体移植物的寿命差异与灭菌、保存及植入方式有关。我们报告了来自单一医疗单位的患者接受抗生素灭菌并在4℃冷藏的主动脉同种异体移植物进行主动脉瓣置换术后长达30年的随访情况。
连续200例患者接受了冠状动脉下同种异体主动脉瓣置换术,随访时间最短20年,最长30年。随访完成率为96%。采用参数风险阶段模型来确定与时间相关风险的增量预测因素。
早期死亡率为1.5%。包括早期死亡在内的Kaplan-Meier精算生存率在10年、20年和25年时分别为81.2%±2.8%(均值±均值的标准误差)、58.0%±3.7%和52%±5.1%。因任何原因再次手术的免再手术率在10年、20年和25年时分别为86.4%±2.6%、39.6%±5.2%和35.0%±5.4%。植入瓣膜较大、因出血再次探查、既往心脏手术及手术等级是再次手术的独立风险因素。再次手术的早期死亡率为5.1%。6例患者发生了同种异体移植物心内膜炎,25年时总体免患率为94%。已知原队列中有7例患者其原同种异体移植瓣膜仍在位存活,其中随访时间最长的为29.8年。
使用抗生素灭菌的同种异体移植物进行冠状动脉下主动脉瓣置换术具有较低的手术死亡率和出色的长期生存率,其耐用性可与任何其他非机械装置相媲美。再次手术的时间相关风险显著降低,且内外径比极佳,使得同种异体主动脉瓣置换术对于较小的主动脉根部尤为理想。